API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
LNZ101 is a fixed dose opthalmic solution of aceclidine (mAChRs agonist) & brimonidine (ADRA2 agonist), which is being evaluated for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
The net proceeds will be used on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $53.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 21, 2024
Details:
The combined will focus on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Graphite Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 21, 2024
Details:
The combined will focus on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: LENZ Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 15, 2023
Details:
The net proceeds will be used on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $53.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 15, 2023
Details:
Brimochol™ PF (combination of carbachol and brimonidine tartrate) is a preservative-free topical ophthalmic solution which is used to lower pressure in the eyes, it is being investigated for the treatment of presbyopia.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimochol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
Brimonidine Tartrate is an Ophthalmic Solution, 0.15%, Of Abbvie Inc.a n Alpha Adrenergic Receptor Agonist, The Drug is Indicated for treatment of Elevated Intraocular Pressure in Patients With Open-Angle Glaucoma Or Ocular Hypertension.
Lead Product(s): Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Alphagan P-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
Details:
Brimochol™ PF (combination of carbachol and brimonidine tartrate) is a preservative-free topical ophthalmic solution which is used to lower pressure in the eyes, it is being investigated for the treatment of presbyopia.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimochol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
The Proceeds will enable LENZ to complete the development and registration and, pending approval, launch LNZ100 (aceclidine) and LNZ101 (aceclidine and brimonidine) in the United States.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sectoral Asset Management
Deal Size: $83.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 07, 2023
Details:
The agency has completed its filing review and accepted for filing the New Drug Application (NDA) for PDP-716 (0.35% brimonidine tartrate) for the treatment of glaucoma.
Lead Product(s): Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: PDP-716
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
Both LNZ100 (aceclidine), and LNZ101 (aceclidine + brimonidine) maintained statistical significance of three-line or greater improvement compared to vehicle for all timepoints including the last measured at 10 hours, 37% and 48% respectively.
Lead Product(s): Brimonidine Tartrate,Aceclidine Hydrochloride
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
The proceeds enable Visiox to finalize and submit the NDAs for its lead assets PDP-716 (brimonidine), manufacture initial inventory, and add key talent as the company expands its commercial team.
Lead Product(s): Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: PDP-716
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Founding Partners
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 03, 2022
Details:
Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify® in U.S. Lumify® is an over-the-counter (OTC) eyedrop that can be used to relieve redness of the eye due to minor eye irritations.
Lead Product(s): Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimonidine Tartrate-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 29, 2022
Details:
Lumify® is an over-the-counter (OTC) eyedrop having Brimonidine Tartrate that can be used to relieve redness of the eye due to minor eye irritations. The agreement also provides Dr. Reddy’s exclusive rights to the product outside the U.S.
Lead Product(s): Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimonidine Tartrate-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 29, 2022
Details:
Under the terms of the agreement, ZKO will be responsible for clinical development and regulatory approval for BRIMOCHOL PF and Carbachol PF in the specified territories, and subsequently the commercialization activities for the products.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimochol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zhaoke Ophthalmology
Deal Size: $130.0 million Upfront Cash: $15.0 million
Deal Type: Licensing Agreement May 11, 2022
Details:
Non-clinical work with BRIMOCHOL PF demonstrating additive effects of brimonidine on the pharmacokinetics and pharmacodynamics of carbachol proved predictive of our clinical results showing contribution of elements in our Phase 2 study.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimochol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
Brimonidine tartrate and timolol maleate ophthalmic solution, 0.2%/0.5% is an alpha-adrenergic receptor agonist with a betaadrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with ocular hypertension.
Lead Product(s): Brimonidine Tartrate,Timolol Maleate
Therapeutic Area: Ophthalmology Product Name: Brimonidine Tartarate/Timolol Maleate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator:
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2022
Details:
Under the license agreement with Ji Xing Pharmaceuticals, LENZ will develop and commercialize LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) for the treatment of presbyopia in Greater China.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ji Xing Pharmaceuticals
Deal Size: $110.0 million Upfront Cash: $15.0 million
Deal Type: Licensing Agreement April 13, 2022
Details:
Results from Phase 2 trial, demonstrate that BRIMOCHOL, a fixed-dose combination of carbachol (a cholinergic miotic agent) and brimonidine tartrate (an alpha-2 agonist), is a safe and effective once-daily eye drop to correct the loss of near vision associated with presbyopia.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimochol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
Company launched Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution which is a generic version of Combigan for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Lead Product(s): Brimonidine Tartrate,Timolol Maleate
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2022
Details:
Proceeds will support clinical and commercial efforts for lead asset BRIMOCHOL™ under investigation for presbyopia as well as new research and development activities in the Company’s drug development pipeline.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimochol
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: LSP
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 10, 2021
Details:
Simbrinza is a fixed combination of a carbonic anhydrase inhibitor and an alpha-2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Lead Product(s): Brinzolamide,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Simbrinza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alcon Inc
Deal Size: $355.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 28, 2021
Details:
The Phase 2 clinical trial is a double-masked, randomized crossover study designed to evaluate the safety and efficacy of two proprietary formulations of BRIMOCHOL topical ophthalmic solution in patients with emmetropic phakic and pseudophakic presbyopia.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: Brimochol
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2021
Details:
Proceeds from the Series A financing will be used to advance the clinical development program for the company’s lead asset, BRIMOCHOL™, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia.
Lead Product(s): Carbachol,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: BRIMOCHOL
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: $36.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 09, 2021
Details:
Results of new investigational in vitro data shows that two benzalkonium chloride preserved eye drops, LUMIFY® redness reliever eye drops and BESIVANCE® 0.6%, indicated complete inactivation of Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2 or COVID-19).
Lead Product(s): Brimonidine Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Lumify
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
New combination ophthalmic solution for the treatment of glaucoma and ocular hypertension, AILAMIDE® Combination Ophthalmic Suspension has been launched in Japan on June 16, 2020.
Lead Product(s): Brimonidine Tartrate,Brinzolamide
Therapeutic Area: Ophthalmology Product Name: Ailamide
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2020
Details:
The decision to stop the trial is based on results of a pre-planned interim sample size analysis conducted by an independent Data Monitoring Committee, which indicated the trial was unlikely to meet its co-primary endpoints upon completion.
Lead Product(s): Brimonidine Tartrate
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020